Wojciech Jurczak

Jan 30, 2025 | onclive.com | Wojciech Jurczak

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell LymphomaDr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable safety profile in older, anthracycline-ineligible patients with previously untreated large B-cell lymphoma.

Jan 23, 2025 | onclive.com | Wojciech Jurczak

CommentaryVideoJanuary 23, 2025Author(s):Fact checked by:Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma. “We think that nemtabrutinib [could be an] alternative therapeutic option in a heavily pretreated follicular lymphoma population.

Dec 7, 2024 | onclive.com | Wojciech Jurczak

CommentaryVideoDecember 7, 2024Author(s):Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma. Wojciech Jurczak, MD, PhD, Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, discusses findings from the phase 2 BELLWAVE-003 study (NCT04728893) of nemtabrutinib in relapsed or refractory follicular lymphoma.

May 16, 2023 | ascopubs.org | Michael Wang |Wojciech Jurczak |Pier Luigi Zinzani |Toby Eyre

Mantle-cell lymphoma (MCL) is an aggressive, rare subtype of B-cell non-Hodgkin lymphoma.